Skip to main content
Fig. 2 | Cell & Bioscience

Fig. 2

From: Exploring the cellular and molecular differences between ovarian clear cell carcinoma and high-grade serous carcinoma using single-cell RNA sequencing and GEO gene expression signatures

Fig. 2

Detection and validation of new biomarkers in OCCC patients. (A) Comparisons of AOC1, GPX3, LEFTY1, S100A, CRABP2 and WFDC2 expression levels as shown in a UMAP plot. Each dot represents a single cell. (B)AOC1, GPX3, LEFTY1, S100A, CRABP2 and WFDC2 expression levels in OCCC (n = 8) and HGSC (n = 8) patients, as determined by real-time PCR. Each dot represents a single individual. (C) Western blot results of AOC1, GPX3, LEFTY1, S100A, CRABP2 and WFDC2 expression in OCCC (n = 4) and HGSC (n = 4) patients. (D) Comparisons of AOC1, GPX3, LEFTY1 and CRABP2 expression in the GSE189553 dataset. (E) Representative images of AOC1, GPX3, LEFTY1, S100A, CRABP2 and WFDC2 in the TMA of OCCC and HGSC samples after immunohistochemical staining. The scale bar is 250 μm. (F) The progression-free survival (PFS) analysis results based on GPX3 level in OCCC patients. P values were calculated by two-sided Wilcoxon test. *: p < 0.05, **: p < 0.01, ***: p < 0.001, ****: p < 0.0001

Back to article page

Cell & Bioscience

ISSN: 2045-3701

Contact us